Roche Holding AG (SWX:RO)
Switzerland
· Delayed Price · Currency is CHF | Market Cap | 229.85B |
| Revenue (ttm) | 62.40B |
| Net Income (ttm) | 8.28B |
| Shares Out | n/a |
| EPS (ttm) | 10.31 |
| PE Ratio | 27.77 |
| Forward PE | n/a |
| Dividend | 9.70 (3.27%) |
| Ex-Dividend Date | Mar 27, 2025 |
| Volume | 16,383 |
| Average Volume | 47,053 |
| Open | 293.80 |
| Previous Close | 303.00 |
| Day's Range | 290.60 - 299.00 |
| 52-Week Range | 229.40 - 333.60 |
| Beta | 0.17 |
| RSI | 31.47 |
| Earnings Date | Apr 25, 2025 |
About Roche Holding AG
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and others; diagn... [Read more]
Financial Performance
In 2024, Roche Holding AG's revenue was 62.40 billion, an increase of 3.23% compared to the previous year's 60.44 billion. Earnings were 8.28 billion, a decrease of -28.01%.
Financial StatementsNews
Roche presents novel therapeutic and diagnostic advancements in Alzheimer's at AD/PD 2025
Basel, 3 April 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that new data were presented at the AD/PD 2025 International Conference on Alzheimer's and Parkinson's Diseases in Vienna, Aust...
Genentech and Roche Present Novel Therapeutic and Diagnostic Advancements in Alzheimer's at AD/PD 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that new data were presented at the AD/PD 2025 International Conferen...
Pharma tariff relief likely short-lived with sector-specific duties on the horizon
Pharmaceutical companies breathed a sigh of relief Wednesday after U.S. President Donald Trump revealed that they would not be subject to reciprocal tariffs — but that reprieve could prove fleeting. T...
Why Is Pharma Giant Roche Stock Trading Lower On Wednesday?
Roche's MUSETTE trial found no additional benefit of ... Full story available on Benzinga.com
Why Is Pharma Giant Roche Stock Trading Lower On Wednesday?
Roche Holdings AG RHHBY on Wednesday announced data from MUSETTE Phase 3 trial of a high dose of Ocrevus (ocrelizumab) intravenous (IV) infusion in adult patients with relapsing multiple sclerosis (RM...
IBD 50 Stock TG Therapeutics Rallies On A Setback For Chief Rival Roche
TG Therapeutics rallied Wednesday after Roche's rival multiple sclerosis treatment, Ocrevus, missed its mark in a study.
TG Therapeutics rises after trial setback for high dose version of Roche’s MS drug
Roche fails in bid to increase dose of MS drug Ocrevus
Roche said on Wednesday that a trial testing higher doses of its multiple sclerosis drug Ocrevus did not show an efficacy benefit over the standard dose, a setback in a bid to further boost usage of t...
Genentech Provides Update on Phase III Ocrevus High Dose Study in People With Relapsing Multiple Sclerosis
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the Phase III MUSETTE trial comparing a high dose of Ocrevus® (o...
Roche provides update on Phase III OCREVUS high dose study in people with relapsing multiple sclerosis
Basel, 02 April 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the Phase III MUSETTE trial comparing a high dose of OCREVUS® (ocrelizumab) intravenous (IV) infusion to the currently ap...
Quest Diagnostics Introduces HPV Specimen Self-Collection for Cervical Cancer Screening
Providers in the United States may now order the FDA-cleared HPV self-collection solution for their patients to use in their offices or other healthcare settings, with goal to reduce barriers to scree...
Organon buys rights to Biogen’s biosimilar targeting Roche’s Actemra
These 16 dividend stocks have ‘high quality yields' if you want to diversify away from the U.S.
Investors and traders might focus on the reasons behind periods of decline or higher volatility in the stock market. But long-term investors have always needed to weather stock-market storms, regardle...
Roche Annual General Meeting 2025
Basel, 25 March 2025 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that its shareholders had approved all proposals of the Board of Directors at its Annual General Meeting. The 616 shareholders...
Roche abandons global diversity targets on concern over U.S. executive orders
Swiss drugmaker Roche has abandoned global targets for a more diverse workforce to avoid penalties from recent U.S. executive orders, the latest in a slew of companies to do so.
Oxford BioTherapeutics Enters into a Strategic Collaboration with Roche to Discover Novel Targets for Antibody-Based Therapeutics for the Treatment of Cancer
Oxford, UK and San Jose, California, 19th March 2025 – Oxford BioTherapeutics (OBT), a clinical stage oncology company with a pipeline of immuno-oncology (IO) and Antibody Drug Conjugate (ADC)-based t...
Roche Holding Has A Canadian Depositary Receipt
Sarepta plunges after death linked to Elevidys
Sarepta Therapeutics (SRPT) stock drops 25% as the company reports a patient death linked to Elevidys, its gene therapy developed with Roche (RHHBY). Read more here.
Roche to share latest scientific advancements from its neuromuscular portfolio at Muscular Dystrophy Association (MDA) 2025 conference
Basel, 17 March 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it will present new data at the Muscular Dystrophy Association (MDA) conference, 16-19 March, 2025, in Dallas, Texas, fro...
Notable healthcare headlines for the week: Merck, Novo Nordisk, J&J and Roche in focus
Discover last week's top S&P 500 healthcare gainers, major market stories, and groundbreaking pharma deals, including weight-loss drug updates.
Roche, Zealand Pharma Strike $5.3 Billion Weight-Loss Therapy Deal
Why Viking Therapeutics and Roche Holdings Popped Today, but Novo Nordisk Stock Dropped
Ignore the noise in GLP-1 stocks. Find the best value instead.
Novo Nordisk Stock Slides After Roche Strikes Weight-Loss Deal
Roche agrees biggest-ever obesity drug deal
Swiss pharma group signs $5.3bn licensing agreement for next-generation treatment made by Zealand Pharma
Roche Inks 'The Largest Obesity Deal To Date' With Zealand Pharma At $5.3 Billion
Roche and Zealand Pharma inked a $5.3 billion deal Wednesday to collaborate on a weight-loss drug in the amylin class.